Stock Rating Report for INHX
|
|
Stock Information
| Ticker |
INHX |
| Company Name |
Inhibitex, Inc |
| Current Price |
$25.85 |
| Previous Close |
$25.85 |
| Industry |
Biotechnology |
| Sector |
HEALTHCARE |
| Long Stop Loss |
Members Only |
| Short Stop Loss |
Members Only |
| Expected Move |
Members Only |
| Optionable? |
Yes
|
StockProphet Ratings
Join today to see our Technical, Fundamental, and Composite Stock Rating for this stock.
Sector Risks
Chart
We use technical analysis and fundamental analysis to recommend ratings for thousands of stocks. If you had a subscription, this space would show our 3 year history of trades for INHX. However, we only show it to our subscribers.
We update our ratings and stop losses EVERY WEEK.
Don't miss out on what we recommend for Inhibitex, Inc next week. Sign up today and start making money!
Demand Fundamentals
|
Demand Technicals
Company Profile
Inhibitex, Inc., a biopharmaceutical company, focuses on the development of differentiated anti-infective products to prevent or treat serious infections. It primarily focuses to treat shingles caused by the varicella zoster virus and chronic infections caused by hepatitis C virus (HCV). Its antiviral product candidates include INX-189, a HCV nucleoside polymerase inhibitor that has completed Phase Ib clinical trials for the treatment of chronic hepatitis C infection- FV-100, an orally available nucleoside analogue prodrug, which is in Phase II clinical trials for the treatment of herpes zoster or shingles. The company is also developing anti-bacterials comprising Staphylococcal Vaccines, which is under Phase I clinical trials to prevent Staphylococcus aureus infections- and Aurexis, a humanized monoclonal antibody that has completed Phase II trials for the treatment of Staphylococcus aureus bloodstream infections in hospitalized patients. It has a license and development collaboration agreement with Pfizer, Inc. for the development of Staphylococcus aureus vaccine for humans. Inhibitex, Inc. was founded in 1994 and is based in Alpharetta, Georgia.
|
Latest News
| Tue, 07 Feb 2012 19:19:28 GMT | BofA Downgrade Sends Achillion Plunging | | Tue, 07 Feb 2012 14:00:00 GMT | A Forward Look, the Year Ahead - Featured Research on Inhibitex, Inc. and Idenix Pharmaceuticals, Inc. | | Mon, 06 Feb 2012 20:11:00 GMT | Inhibitex downgraded by JMP Securities | | Mon, 06 Feb 2012 17:57:00 GMT | 3 Industries and 3 Stocks Riding a 2012 M&A Boom | | Sun, 05 Feb 2012 09:56:23 GMT | 3 M&A Arbitrage Opportunities | | Fri, 03 Feb 2012 19:07:24 GMT | Gilead Up 6% After Positive Hep-C Trial | | Fri, 03 Feb 2012 16:13:06 GMT | Idenix Falls Casualty to Gilead Hep C Hoopla | | Fri, 03 Feb 2012 12:48:47 GMT | Gilead Wows With New Hep C Data, Boxing Out Poor 2012 Guidance | | Wed, 01 Feb 2012 21:16:19 GMT | Illogical Biotech Valuations Create Value And Value Traps | | Wed, 01 Feb 2012 20:35:35 GMT | Got 401K? Part II in HD | | Wed, 01 Feb 2012 16:47:08 GMT | Easing The Pain: Why Investment In Bio-Pharma Is A Worthy Cause | | Wed, 01 Feb 2012 05:01:51 GMT | Achillion, Idenix could miss hep-C merger bonanza | | Tue, 31 Jan 2012 08:26:43 GMT | Canaccord Genuity Rates These 8 Healthcare Stocks A Buy | | Mon, 30 Jan 2012 20:49:19 GMT | Best Performing Stocks Year To Date | | Mon, 30 Jan 2012 20:26:16 GMT | Johnson & Johnson: The Turnaround Is Starting And I Am A Buyer | | Mon, 30 Jan 2012 14:53:13 GMT | Has Gilead Sciences Become the Perfect Stock? | | Sat, 28 Jan 2012 10:21:18 GMT | [$$] Dow, S&P End Week With a Dull Thud | | Fri, 27 Jan 2012 18:33:42 GMT | Idenix Pharmaceuticals Shares Plunged Temporarily: What You Need to Know | | Fri, 27 Jan 2012 00:00:00 GMT | Amgen, Celgene, Roche Deals Signal M&A Frenzy for Drug Companies | | Thu, 26 Jan 2012 19:00:25 GMT | Bristol-Myers Misses on all Fronts | News provided by Yahoo! Finance |
|
|
|
|
